Сравнение
Dulaglutide vs. Semaglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
923950-08-7
910463-68-2
Молекулярная масса
59670 g/mol
4113.6 g/mol
Период полувыведения
110 h
165 h
Последовательность
GLP-1(7-37)-Variante kovalent verbunden mit modifiziertem humanen IgG4-Fcmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerМеханизм действия
Dulaglutide
Dulaglutide consists of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc. The Fc fusion increases molecular weight substantially (~60 kDa), reduces renal filtration and extends the half-life to several days. GLP-1 receptor activation glucose-dependently stimulates insulin secretion, inhibits glucagon, delays gastric emptying and modulates central satiety signalling.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
5
4
из них на людях
5
3
Зафиксированные эффекты
3
3
Открытые противоречия
1
1
Задокументированные нежелательные явления
2
5
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Dulaglutide and Semaglutid?
- Dulaglutide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Dulaglutide: GLP-1 receptor agonist designed as a fusion protein of two modified GLP-1(7-37) sequences covalently linked to a human IgG4-Fc fragment. FDA-approved 2014 (Trulicity) for type 2 diabetes; EMA approval 2014. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Dulaglutide or Semaglutid?
- The highest available evidence level is "РКИ на людях" for Dulaglutide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Dulaglutide and Semaglutid in Germany and the United States?
- Германия: Dulaglutide — Рецептурный, Semaglutid — Рецептурный. США: Dulaglutide — Рецептурный, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.